A cost-benefit analysis of genetic screening test for breast cancer in Iran
Abstract Background This study aimed to evaluate the implementation of the population- and family history (FH) -based screening for BReast CAncer (BRCA) in Iran, a country where less than 10% of breast cancer cases are attributable to a gene mutation. Methods This was an economic evaluation study. T...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-12003-4 |
| _version_ | 1797274298248855552 |
|---|---|
| author | Zahra Meshkani Najmeh Moradi Ali Aboutorabi Hiro Farabi Nazi Moini |
| author_facet | Zahra Meshkani Najmeh Moradi Ali Aboutorabi Hiro Farabi Nazi Moini |
| author_sort | Zahra Meshkani |
| collection | DOAJ |
| description | Abstract Background This study aimed to evaluate the implementation of the population- and family history (FH) -based screening for BReast CAncer (BRCA) in Iran, a country where less than 10% of breast cancer cases are attributable to a gene mutation. Methods This was an economic evaluation study. The Benefit-Cost Ratio (BCR) for genetic screening test strategies in Iranian women older than 30 was calculated. To this end, the monetary value of the test was estimated using the willingness-to-pay (WTP) approach using the contingent valuation method (CVM) by payment card. From a healthcare perspective, direct medical and non-medical costs were considered and a decision model for the strategies was developed to simulate the costs. A one-way sensitivity analysis assessed the robustness of the analysis. The data were analyzed using Excel 2010. Results 660 women were included for estimating WTP and 2,176,919 women were considered in the costing model. The cost per genetic screening test for population- and FH-based strategies was $167 and $8, respectively. The monetary value of a genetic screening test was $20 and it was $27 for women with a family history or gene mutation in breast cancer. The BCR for population-based and FH-based screening strategies was 0.12 and 3.37, respectively. Sensitivity analyses confirmed the robustness of the results. Conclusions This study recommends the implementation of a FH-based strategy instead of a population-based genetic screening strategy in Iran, although a cascade genetic screening test strategy should be evaluated in future studies. |
| first_indexed | 2024-03-07T14:56:23Z |
| format | Article |
| id | doaj.art-57cc6fd2312747bf8158c8a35e2b3af8 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-07T14:56:23Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-57cc6fd2312747bf8158c8a35e2b3af82024-03-05T19:23:16ZengBMCBMC Cancer1471-24072024-03-012411910.1186/s12885-024-12003-4A cost-benefit analysis of genetic screening test for breast cancer in IranZahra Meshkani0Najmeh Moradi1Ali Aboutorabi2Hiro Farabi3Nazi Moini4Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical SciencesPopulation Health Sciences Institute, Newcastle UniversityDepartment of Health Economics, School of Health Management and Information Sciences, Iran University of Medical SciencesBarts and The London Pragmatic Clinical Trial Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of LondonBreast Cancer Research Centre, Motamed Cancer Institute, ACECRAbstract Background This study aimed to evaluate the implementation of the population- and family history (FH) -based screening for BReast CAncer (BRCA) in Iran, a country where less than 10% of breast cancer cases are attributable to a gene mutation. Methods This was an economic evaluation study. The Benefit-Cost Ratio (BCR) for genetic screening test strategies in Iranian women older than 30 was calculated. To this end, the monetary value of the test was estimated using the willingness-to-pay (WTP) approach using the contingent valuation method (CVM) by payment card. From a healthcare perspective, direct medical and non-medical costs were considered and a decision model for the strategies was developed to simulate the costs. A one-way sensitivity analysis assessed the robustness of the analysis. The data were analyzed using Excel 2010. Results 660 women were included for estimating WTP and 2,176,919 women were considered in the costing model. The cost per genetic screening test for population- and FH-based strategies was $167 and $8, respectively. The monetary value of a genetic screening test was $20 and it was $27 for women with a family history or gene mutation in breast cancer. The BCR for population-based and FH-based screening strategies was 0.12 and 3.37, respectively. Sensitivity analyses confirmed the robustness of the results. Conclusions This study recommends the implementation of a FH-based strategy instead of a population-based genetic screening strategy in Iran, although a cascade genetic screening test strategy should be evaluated in future studies.https://doi.org/10.1186/s12885-024-12003-4Breast cancerBRCA1 proteinBRCA2 proteinScreeningCost-benefit analysisWillingness to pay |
| spellingShingle | Zahra Meshkani Najmeh Moradi Ali Aboutorabi Hiro Farabi Nazi Moini A cost-benefit analysis of genetic screening test for breast cancer in Iran BMC Cancer Breast cancer BRCA1 protein BRCA2 protein Screening Cost-benefit analysis Willingness to pay |
| title | A cost-benefit analysis of genetic screening test for breast cancer in Iran |
| title_full | A cost-benefit analysis of genetic screening test for breast cancer in Iran |
| title_fullStr | A cost-benefit analysis of genetic screening test for breast cancer in Iran |
| title_full_unstemmed | A cost-benefit analysis of genetic screening test for breast cancer in Iran |
| title_short | A cost-benefit analysis of genetic screening test for breast cancer in Iran |
| title_sort | cost benefit analysis of genetic screening test for breast cancer in iran |
| topic | Breast cancer BRCA1 protein BRCA2 protein Screening Cost-benefit analysis Willingness to pay |
| url | https://doi.org/10.1186/s12885-024-12003-4 |
| work_keys_str_mv | AT zahrameshkani acostbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT najmehmoradi acostbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT aliaboutorabi acostbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT hirofarabi acostbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT nazimoini acostbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT zahrameshkani costbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT najmehmoradi costbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT aliaboutorabi costbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT hirofarabi costbenefitanalysisofgeneticscreeningtestforbreastcanceriniran AT nazimoini costbenefitanalysisofgeneticscreeningtestforbreastcanceriniran |